Codexis, Inc. (NASDAQ:CDXS) Shares Bought by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC lifted its holdings in shares of Codexis, Inc. (NASDAQ:CDXS) by 30.3% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 75,951 shares of the biotechnology company’s stock after purchasing an additional 17,657 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Codexis were worth $362,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in CDXS. Intech Investment Management LLC purchased a new stake in Codexis during the 3rd quarter worth approximately $66,000. Kingswood Wealth Advisors LLC purchased a new position in Codexis in the 4th quarter valued at approximately $79,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Codexis in the fourth quarter worth $82,000. Jackson Square Capital LLC purchased a new stake in shares of Codexis during the fourth quarter worth $210,000. Finally, Inspire Investing LLC acquired a new stake in shares of Codexis in the fourth quarter valued at $405,000. Hedge funds and other institutional investors own 78.54% of the company’s stock.

Codexis Trading Down 7.0 %

NASDAQ:CDXS opened at $2.13 on Monday. Codexis, Inc. has a 12-month low of $2.00 and a 12-month high of $6.08. The firm has a market cap of $176.44 million, a PE ratio of -2.45 and a beta of 2.35. The company has a current ratio of 3.21, a quick ratio of 3.15 and a debt-to-equity ratio of 0.39. The stock has a fifty day moving average price of $3.46 and a 200 day moving average price of $3.93.

Codexis (NASDAQ:CDXS) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.09). Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. The company had revenue of $21.46 million during the quarter, compared to analysts’ expectations of $27.41 million. Sell-side analysts anticipate that Codexis, Inc. will post -0.77 earnings per share for the current fiscal year.

Codexis Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.